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Background: The term “adrenal fatigue” (“AF”) has been used by some doctors, healthcare providers, and the
general media to describe an alleged condition caused by chronic exposure to stressful situations. Despite this,
“AF” has not been recognized by any Endocrinology society, who claim there is no hard evidence for the existence.
The aim of this systematic review is to verify whether there is substantiation for “AF”.
Methods: A systematic search was performed at PUBMED, MEDLINE (Ebsco) and Cochrane databases, from the
beginning of the data until April 22nd, 2016. Searched key words were: “adrenal” + “fatigue”, “adrenal” + “burnout”,
“adrenal” + “exhaustion”, “hypoadrenia”, “burnout” + “cortisol”, “fatigue” + “cortisol”, “clinical” + “burnout”, “cortisol” +
“vitalility”, “adrenal” + “vitality”, and “cortisol” + “exhaustion”. Eligibility criteria were: (1) articles written in English, (2)
cortisol profile and fatigue or energy status as the primary outcome, (3) performed tests for evaluating the adrenal
axis, (4) absence of influence of corticosteroid therapy, and (5) absence of confounding diseases. Type of questionnaire
to distinct fatigued subjects, population studied, tests performed of selected studies were analyzed.
Results: From 3,470 articles found, 58 studies fulfilled the criteria: 33 were carried in healthy individuals, and 25 in
symptomatic patients. The most assessed exams were “Direct Awakening Cortisol” (n = 29), “Cortisol Awakening
Response” (n = 27) and “Salivary Cortisol Rhythm” (n = 26).
Discussion: We found an almost systematic finding of conflicting results derived from most of the studies methods
utilized, regardless of the validation and the quality of performed tests. Some limitations of the review include: (1)
heterogeneity of the study design; (2) the descriptive nature of most studies; (3) the poor quality assessment of fatigue;
(4) the use of an unsubstantiated methodology in terms of cortisol assessment (not endorsed by endocrinologists);
(5) false premises leading to an incorrect sequence of research direction; and, (6) inappropriate/invalid conclusions
regarding causality and association between different information.
Conclusion: This systematic review proves that there is no substantiation that “adrenal fatigue” is an actual medical
condition. Therefore, adrenal fatigue is still a myth.
Keywords: Adrenal depletion, Adrenal fatigue, Cortisol, Adrenal insufficiency, Burnout, Fatigue
Abbreviations: 24 h UFC, 24-h urinary free cortisol; ACTH, Adrenocorticotropic hormone; ADAS, Abbreviated
dyadic adjustment scale; AF, Adrenal fatigue; AUC, Estimated cortisol release (area under the curve); BFI, Brief
fatigue inventory; CAR, Cortisol awakening response; CFQ, Chalder fatigue questionnaire; CFS, Chronic fatigue
syndrome; CST, Cosyntropin stimulation test; DAC, Direct awakening cortisol; DCSRD, Diagnosis criteria of
stress-related exhaustion disorder; DHEA-S, Dehydroepiandrosterone sulfate; DST, Dexamethasone suppression test;
FAQ, Fatigue assessment questionnaire; FMG, Fibromyalgia; FSE, Fatigue severity scale; H/B, Healthy/Burnout;
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HRFS, HIV-related fatigue scale; Maastricht, Maastricht vital exhaustion questionnaire; Maslach, Maslach burnout
inventory; MFI, Multidimensional fatigue inventory; MP, Memory performance; MSC, morning serum cortisol
(& salivary); MST, Mental stress tests; NC-WHO, Neurasthenia criteria; NRWS, Need for recovery from work scale;
NSC, Night salivary cortisol; POMS, Profile of mood states; SCR, Salivary cortisol rhythm; SEQ, Exclusion with
stress-energy questionnaire; SF-36, Short form health servey 36; SMBQ, Shirom-melamed burnout questionnaire;
SOFI, Swedish occupational fatigue inventory; UFC, 24 h Urinary free cortisolBackground
The term “adrenal fatigue” (“AF”) has been used by
some doctors, healthcare providers, and the general
media to describe an alleged condition caused by
chronic exposure to stressful situations. According to
this theory, chronic stress could potentially lead to
“overuse” of the adrenal glands, eventually resulting in
their functional failure. In a recent search on Google
(April 22, 2016), “adrenal fatigue” provided 640,000 re-
sults, and the association of the two words exhibited
1,540,000 findings. Despite this, “adrenal fatigue” has
not been recognized by any endocrinology societies to
date, who claim there is no evidence for the existence
of this syndrome [1].
Conversely, some medical societies, although unrecognized
by American Board of Medical Specialties and Associ-
ation of American Medical Colleges [2, 3], claim that
adrenal fatigue is a real and underdiagnosed disease
[4, 5]. According to these societies, to screen for “AF”
in patients, a questionnaire developed by Dr. Wilson,
who is reportedly the first person to describe this sup-
posed syndrome, is recommended to be used [6]. In
addition, patients suspected of “AF” are now being
tested for serum basal cortisol levels and salivary cor-
tisol rhythm. Those who present impaired results from
these tests are then treated with corticosteroids, re-
gardless of the etiology. As a result, corticosteroids
(mainly hydrocortisone) are probably being prescribed
to a large number of patients, as at least 24,000 health
providers [7] are instructed by one medical society
(The American Academy of Anti-Aging Medicine – A4M)
to prescribe corticosteroids in these cases.
Arguments for corticosteroid use as a treatment for
“claimed AF” include: [1] the immediate and significant
improvement seen in patients who are prescribed cor-
ticosteroid, and [2] the long and extensive clinical symp-
tomatology of this alleged disease, which shows a slow
depletion before clinical and severe hypocortisolism en-
sues [4–6]. Moreover, others claim that endocrinologists
use much too strict diagnostic criteria before prescribing
corticosteroids, and thus, many sufferers would not be
receiving adequate treatment [4, 6]. However, there are
logical counterarguments to routine corticosteroid use
in these patients. First, corticosteroids promote a sense
of wellbeing (usually temporary), regardless of thepatient’s condition. Second, even at low and physio-
logical doses, corticosteroids increase the risk for several
disorders, such as psychiatric disorders [8–11], osteopor-
osis [12], myopathy [13], glaucoma [14], metabolic disor-
ders [14, 15], sleep disturbances [16] and cardiovascular
diseases [17, 18].
Therefore, is “adrenal fatigue” an actual disorder? Is
fatigue related to depleted adrenal function? Does fa-
tigued healthy subjects present relative adrenal failure?
Is adrenal involved in the pathophysiology of fatigue in
diseases? Which tests were performed in order to es-
tablish markers or triggers? The aim of this systematic
review was to determine the correlation between ad-
renal status and fatigue states, including the recently
described “burnout” or “burnout syndrome”, and other
fatigue-related diseases. The primary objective was to
evaluate the methodology for fatigue status assessment,
including cortisol tests, and to examine the results of
studies involving cortisol and fatigue correlation.
Methods
Search strategies
The PRISMA protocol for systematic reviews was uti-
lized for this study design. A systematic search was
conducted through the electronic PUBMED, MEDLINE
(Ebsco), and COCHRANE databases, from the begin-
ning of the data until April 22, 2016. The search strat-
egy included the following keywords: (1) “adrenal +
fatigue”; (2) “adrenal + burnout”; (3) “adrenal + exhaus-
tion”; (4) “adrenal” + “fatigue”; (5) “hypoadrenia”; (6)
“cortisol” + “fatigue”; (7) “cortisol” + “burnout”; (8)
“clinical” + “burnout”; (9) “cortisol” + “vitality”; (10) “ad-
renal” + “vitality”; and (11) “cortisol” + “exhaustion”,
where “a + b” means “a” and “b” together in the exact
expression, and “a” +”b” means that both words needed
to be contained in the article, but not necessarily to-
gether. Although the terms “adrenal + fatigue” and “ad-
renal” + “fatigue” were searched, as articles found using
the first criteria were also found using the second cri-
teria, further analysis were performed for the exact
expression that matched with the disease. We also
analyzed articles mentioned within identified studies
whenever the alleged disorder, or a similar situation,
were described (such as cortisol profile and exhaustion
or fatigued patients).
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All studies were evaluated by the two reviewers (F.A.C.
and C.E.K.) after removal of duplicate articles, according
to: (1) authorship, (2) journal, (3) publication date, (4)
studied population, (5) definition of “fatigue”, “exhaus-
tion”, and “burnout”, (6) study design and methods, (7)
analysis methods to assess adrenal axis, (8) results, (9)
conclusions, and (10) study variables and bias.
Inclusion and exclusion criteria
Inclusion criteria were: (1) whole article written in English,
(2) cortisol profile and fatigue or energy status as the pri-
mary outcome, (3) specific tests performed for evaluating
the adrenal axis, (4) absence of corticosteroid therapy, (5)
absence of confounding diseases that would lead to an
impaired cortisol status caused by the disorder itself
(such as depression, alcoholism, and morbid obesity).
Studies with a merely description about adrenal axis
impairment with no tests performed were excluded.
Quality assessment
The abstract of each of identified study was analyzed by
one of the authors (F.A.C.), and was excluded if it did not
meet the eligibility criteria. The studies that fulfilled the
inclusion criteria were entirely evaluated regarding the ra-
tionale, method design, primary outcome, assessment of
fatigue, statistical analysis, results, discussion, and conclu-
sions, in order to improve data quality. Those studies that
presented any bias in the methodology, results, or inter-
pretation of the exposed data, which could be reflected in
the analysis of the study as a whole, were also excluded.
Statistical analysis
Each of the studied populations, each of the question-
naires and each of the tests performed were quantified,Fig. 1 Study selectionwhereas tests results were analyzed in terms of percent-
age of type of responses for each of the tests performed.
Results were analyzed in general and according to the
underlying disease.Results
Study selection
In total, 3,470 articles were identified. A summary of the
study selection is shown in Fig. 1. The search for “ad-
renal” + “burnout” yielded 56 studies; “adrenal” + “ex-
haustion” yielded 446 articles; “adrenal” + “fatigue”
yielded 1,353 articles; “fatigue” + “cortisol” yielded 1,128
articles; “cortisol” + “burnout” yielded 102 articles; “corti-
sol” + “vitality” yielded 37 articles; “adrenal” + “vitality”
yielded 53 articles; “hypoadrenia” yielded 9 articles arti-
cles (“hypoadrenocorticism” yielded 1,302 articles but is
used to refer to hypocortisolism in animals, and there-
fore, was not included here); and “cortisol” + “exhaus-
tion” yielded 286 articles. Twelve studies were excluded
because they were written in languages other than
English, 1,989 were excluded because there was no
relation with the purpose of the systematic review,
whereas 905 articles of interest were duplicates. Of
the 564 remaining studies, 504 had only descriptive
characteristics or contained results already presented
in another study (in which tests were performed), and
therefore were excluded. Two studies were excluded
because despite of the correlation between cortisol
profile and burnout or multiple sclerosis, they did not
perform correlation between fatigue and cortisol, but
other aspects, as depression and pain [19, 20]. For the
systematic review, we analyzed all the included and
not excluded studies, which represent a total of 58 ar-
ticles (1.67 % of the original search) (Table 1).







Population Questionnaire Tests Results Comments
McLennan
[21]





FAQ DAC, CAR, SCR, NSC ↑NSC, ↑AUC, Nl CAR,
Nl DAC, ↓SCR
Pts. mostly on chemotherapy
(ChTx); schemes not specified.
No controls, only correlation
between fatigue levels and tests.
ChTx related to worse fatigue.
Initial tests performed during,





FAQ DAC, CAR, SCR, NSC ↑AUC, ↑CAR, ↑NSC,
↑SCR, Nl DAC
Second test of the study,
performed after 14 weeks
of procedures.
Sjors [25] 2015 220 H/B SMBQ DAC, CAR ↓CAR, ↑DAC Results normalized after
adjustment of anti-depressive
use; SCR results not provided
Oosterholt
[28]
2015 91 H/B Maslach DAC, CAR, SCR,
AUC, CAR 60 min
Nl SCR, ↓CAR, Nl AUC,
Nl CAR 60 min, ↓DAC
Control of variations did not
change results




MSC, MST Nl MSC, Nl MST MST: Nl (women), reduced (men);
MSC: Nl (men), reduced (women).
Mental arithmetic and public
speech stressors also performed
Lennartsson
[24]










Tao [23] 2015 171 H/B Maslach MSC, ACTH ↑ACTH, ↑MSC
Jonsson [29] 2015 51 H/B SMBQ MSC, MST Nl MSC, ↓MST
Lennartsson
[27]






Nl MSC, Nl MST,
Nl ACTH, Nl
post-TSST ACTH
Severe BO: lower ACTH, cortisol
response to TSST vs controls,
whereas low BO: higher ACTH,
cortisol responses vs controls
Schmaling
[26]
2015 62 Healthy ADAS AUC, SCR ↓AUC, ↓SCR 31 couples studied, one of which





CFQ DAC, CAR, SCR, NSC Nl DAC, Nl CAR,
Nl NSC, Nl SCR
**Colocar como SAUDÁVEL –
porque é só lombalgia (increased
CAR in Low back pain)
Powell [67] 2015 76 Multiple
Sclerosis
CFQ DAC, CAR, SCR ↓DAC, ↑CAR,
Nl SCR
Sleep disorders excluded;
adjusted for depressive symptoms;
NSC not published. Multiple
sclerosis had increased awakening
cortisol and decreased CAR
Cruz [70] 2015 43 Breast
cancer




2014 1043 H/B Maslach DAC, CAR, SCR, NSC ↑DAC, ↓CAR,
↑SCR, ↓NSC
Only BO; Groups of severe distress
or depression not included
Aggarwal [30] 2014 227 Healthy CFQ MSC, NSC, 0.25 mg
DST, DHEA-S
Nl MSC, Nl NSC,
Nl 0.25 mg DST,
↓DHEA-S
Evaluation of chronic, widespread
pain, chronic orofacial pain,
chronic fatigue (but not CFS),
irritable bowel syndrome
Tell D [71] 2014 130 Breast
cancer
MFI DAC, CAR, SCR, NSC ↓CAR, ↓SCR, ↑DAC, ↑NSC Post-surgery breast cancer,
regardless of ChTx. Not
adjusted to sleeping patterns
Wolfram [32] 2013 53 H/B Maslach MSC, 1 mcg CST,
DST/CRH test (1.5 mg
DST + 100 mcg CRH)
Nl MSC, ↓post-1 mcg
ACTH, Nl ACTH and
cortisol DST-CRH
High over-commitment present
blunted serum and salivary
cortisol and ACTH responses
to DST-CRH test





MSC, post-stress Nl MSC, Nl post-stress A complex test sequence was
performed but not reproduced
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Table 1 Summary of selected studies (Continued)
Eek [34] 2012 581 Healthy SOFI-20 DAC, CAR, NSC,
SCR, MSC
Nl DAC, Nl CAR, Nl
NSC, Nl SCR, Nl MSC
Women: reduced awakening,
increased CAR, increased SCR;
Men: increased awakening and
reduced CAR – when fatigued
Sjors [35] 2012 247 H/B DCSRD
and SMBQ
DAC, 15 min CAR Nl DAC, Nl 15 min
CAR
Rahman [54] 2011 30 CFS Previous
Dx – No
questionnaire




2010 64 H/B Maslach DAC, CAR Nl DAC, Nl CAR
Kumari [38] 2009 4,299 Healthy SF-36 DAC, CAR, NSC, SCR ↓DAC, ↓CAR,
↑NSC, ↓SCR
Adjusted for WC, BMI, sleep
duration, CVD medication,
depressive symptoms, smoking,
alcohol intake provides Nl
awakening but lower SCR
Osterberg
[39]
2009 304 H/B Maslach DAC, CAR, NSC, SCR Nl DAC, Nl CAR,
↓NSC, ↑SCR




2009 279 H/B Maslach and
Maastricht
AUC, SCR Nl AUC, Nl SCR DAC and CAR not done;
conclusions different from results.
For AUC, Low BO: Nl, moderate:
increased, severe: decreased
Rydstedt [40] 2009 76 Healthy NRWS DAC, NSC Nl DAC, Nl NSC
Papadopoulos
[55]
2009 38 CFS CFQ and
SF-36
MSC, AUC, morning
AUC, 0,5 mg DST
↑MSC, ↑AUC, ↑MAUC,
Nl 0.5 mg DST
Data on absolute cortisol levels
at each point not published.
DST reduction evaluated by
percent reduction.
Bay [72] 2009 75 Post
traumatic
brain injury
POMS AUC Nl AUC Correlation between brain injury-
related fatigue level and cortisol
AUC. Basal and NSC results not
reported; SCR not evaluated.
Sudhaus [73] 2009 43 Chronic
Lombalgia
MFI DAC, CAR, MAUC ↓CAR, Nl DAC, Nl MAUC
(correlation between
fatigue levels among
low back pain subjects)
Lindeberg [36] 2008 78 Healthy SF-36 DAC, CAR, NSC, SCR Nl DAC, ↓CAR,
Nl NSC, ↓SCR
Sertoz [42] 2008 72 H/B Maslach Basal and post
1.0 mcg DST cortisol




2008 101 H/B Maslach and
Maastricht
DAC, CAR, NSC, SCR,
0.25 mg DST
Nl DAC, Nl CAR, Nl NSC,
Nl SCR, ↓0.25 mg DST
Nater [57] 2008 185 CFS SF-36
and MFI
DAC, CAR, MAUC Nl DAC, Nl CAR, ↓MAUC
Torres-Harding
[56]
2008 108 CFS FSE AUC, SCR Nl AUC, Nl SCR Multiple psychological tests
performed. Data on NSC,
basal and CAR not published.
Sonnenschein
[45]
2007 42 H/B Maslach CAR, 0.5 mg DST,
DHEA-S
Nl CAR, Nl 0.5 mg DST,
Nl DHEA-S
Adjusted for depression, sleep
quality. Awakening levels and
each level graphics not available
Harris [44] 2007 44 Healthy SF-36 DAC, CAR, NSC, SCR Nl DAC, Nl CAR, Nl NSC,
Nl SCR
Other aspects also correlated:
complains, job stress and
demand, QOL and coping.
Adjusted for coffee and tobacco.
Langelaan [46] 2006 55 H/B Maslach DAC, CAR, 0.5 mg
DST, DHEA-S
Nl DAC, Nl CAR, Nl 0.5 mg
DST, Nl DHEA-S
Engaged work also compared and
had stronger suppression in DST
Mommersteeg
[47]
2006 109 Healthy NC-WHO DAC, CAR, 0.5 mg
DST, SCR, AUC, NSC
Nl DAC, Nl CAR, Nl NSC, Nl
SCR, Nl 0.5 mg DST, Nl AUC
Barroso [74] 2006 40 HIV HRFS MSC, NSC ↓MSC, ↑NSC
Jerjes [58] 2006 80 CFS CFQ UFC, TCM ↓UFC, Nl TCM
Grossi [48] 2005 64 H/B SMBQ DAC, CAR ↓DAC, ↑CAR Groups were high x moderate x low
BO score; correlation was significant
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Table 1 Summary of selected studies (Continued)
Segal [59] 2005 40 CFS No
questionnaire
MSC, 1 mcg CST ↓ MSC, ↓1 mcg CST DHEA-S collected only in CFS.
No questionnaires used.
Jerjes [60] 2005 35 CFS CFQ MSC, SCR, NSC, AUC ↓MSC, ↓SCR, ↓AUC ↓,
Nl NSC
Bower [75] 2005 29 Breast
cancer
SF-36 DAC, AUC, SCR, NSC ↑AUC, ↓SCR, Nl DAC,
↑NSC
Post-ChTx (regardless of time)
complete cancer remission and
exclusion of other disorders
McLean [76] 2005 55 Fybro-
mialgia
SF-36 DAC, 60 min CAR,
SCR, AUC, NSC
Nl DAC, Nl 60 min CAR,




FMG subjects presented Nl
DAC and CAR, as controls.
Roberts [62] 2004 92 CFS CFQ and
SF-36
DAC, CAR, MAUC Nl DAC, ↓CAR, ↓MAUC
Crofford [61] 2004 72 CFS/FMG POMS ACTH, MSC, SCR,
NSC, AUC
Nl ACTH, Nl SCR,
Nl NSC, ↓AUC, Nl MSC
Tests performed in: CFS, FMG and
CFS + FMG; FMG w/o fatigue had
Nl AUC and increased BMC levels





evaluation – Nl initial cortisol.
De Vente [49] 2003 45 H/B Maslach DAC, MSC, post-TSST ↑DAC, ↑MSC, Nl post-TSST
Gaab [63] 2002 42 CFS MFI DAC, CAR, SCR,
0.5 mg DST
↓0.5 mg DST, Nl AUC,
Nl CAR, Nl DAC, Nl SCR,
Nl NSC
CAR also performed at 15,
45 and 60 min.
Dekkers [77] 2000 53 Rheumatoid
Arthritis
MFI DAC, CAR, SCR, AUC Nl AUC, Nl SCR Nl,
↓DAC, ↑CAR
5/25 subjects with RA taking
prednisone (5–10 mg/d); RS
subjects had smaller SCR,
increased AM cortisol and
decreased CAR. 15 and 45 min
CAR also performed.
Melamed [51] 1999 111 H/B SMBQ and
Maastricht
MSC and 4 PM
cortisol
↑MSC, Nl 4 PM cortisol




15 min and 60 min CAR
also performed
Strickland [65] 1998 74 CFS Not
specified/
detailed
MSC, NSC ↓NSC, Nl MSC Adjusted for depression
Young [66] 1998 45 CFS NC-WHO UFC, SCR, MSC, AUC Nl UFC, Nl SCR,
Nl MSC, Nl AUC
Scott [64] 1998 28 CFS Not specified
(not detailed)
MSC, ACTH, 100 mcg
CRH cortisol
stimulation
Nl MSC, Nl ACTH, CRH
stim test: ↓cortisol, ↓ACTH





↑CST, Nl DST, Nl OGTT,
Nl MSC, Nl ACTH
Full article not assessed – not
in PUBMED or other database
Questionnaires: SMBQ shirom-melamed burnout questionnaire, BFI brief fatigue inventory, CFQ chalder fatigue questionnaire, Maslach maslach burnout inventory,
SF-36 short form health survey 36, NC-WHO neurasthenia criteria, DCSRD diagnosis criteria of stress-related exhaustion disorder, SEQ stress-energy questionnaire,
ADAS, abbreviated dyadic adjustment scale, MFI multidimensional fatigue inventory, FAQ fatigue assessment questionnaire, MP memory performance,
POMS profile of mood states, Stress Tasks, FSE fatigue severity scale, SOFI Swedish occupational fatigue inventory, Maastricht Maastricht vital exhaustion
questionnaire, NRWS need for recovery from work scale, HRFS HIV-related fatigue scale, WC waist circumference
Other abbreviations: CFS chronic fatigue syndrome, H/B healthy/burnout, 24 h-UFC 24-h urinary free cortisol, FMG fibromyalgia; ↑: Increased or elevated;
↓: Decreased or reduced; →: Unchanged; Nl: Normal
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Among the 58 studies included, 33 (56.9 % of the selected
studies) were performed in healthy subjects [21–53], since
we considered “burnout” not an actual disorder but in-
stead a stressful condition presented by some groups of
health workers. Despite the several studies describing cor-
tisol impairment in Chronic Fatigue Syndrome (CFS), only
13 (22.4 %) studies performed an actual assessment ofthe hypothalamic–pituitary–adrenal (HPA) axis [54–66].
Twelve studies (20.7 %) were found in which tests for cor-
tisol profiling were performed for other diseases [67–77].
However, for analysis purposes, one study [69] was divided
into two studies as it performed two distinct protocols at
different moments. Among these, five were done per-
formed in patients with a diagnosis of breast cancer who
had undergone or were undergoing chemotherapy. One
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compared patients with chronic lower pain, one with
rheumatoid arthritis, one with post brain injury, two
with multiple sclerosis, and one involved patients with
human immunodeficiency virus (HIV) and CFS. One
study evaluated both patients with fibromyalgia and pa-
tients with CFS in different groups.
The median number of tested subjects in the 58 studies
was 72 (range: 16–4,299). The median numbers of
participants in articles involving healthy individuals,
patients with CFS, or patients with other diseases
were 76 (16–4,299), 45 (28–185), and 65 (29–1150),
respectively. The largest number of healthy subjects
included groups of workers whose cortisol results
were compared to exhaustion and fatigue status, in an
attempt to discriminate correlations between cortisol
and energy levels. One study involving 4,299 individ-
uals was responsible for more subjects than the sum
of all the other studies.
Methods used to evaluate fatigue in the general study
population
Some authors utilized more than one method to com-
pare the different patients and were included in multiple
groups. A summary of all the methods used to assess fa-
tigue, and their results, is shown in Table 2. Among the
58 studies, 27 (46.6 %) utilized the Cortisol Awakening
Response (CAR) to assess the HPA axis. This method is
based on previous studies [77–81] that indicate cortisol
levels rise by 50 % on average within 30 min of waking
as a physiological response to stay alert, with a blunted
CAR resulting in fatigue symptoms. For the CAR, saliv-
ary cortisol is collected immediately on waking (t = 0)
and again 30 min later (t = 30), and the difference (delta
cortisol) between the two measurements are analyzed.
Among the 27 studies that employed CAR, fourteen
(51.9 %) showed a normal response, nine (23.3 %) had a
diminished delta cortisol, and four (14.8 %) demon-
strated an increased delta cortisol.
Another method that became widely used to evaluate
exhaustion/burnout/fatigue states is the salivary cortisol
rhythm (SCR), which evaluates the change in cortisol
levels between morning, afternoon, and late night. A
total of 26 studies evaluated SCR (44.8 %). Some hetero-
geneity in the method was found between studies, but in
general, salivary cortisol was collected at 8 AM, 4 PM,
and 10–11 PM. While the SCR is considered as another
fatigue marker [82, 83], like the CAR, there is no justifi-
cation for considering this as an etiology for “adrenal fa-
tigue”. Sixteen (61.5 %) studies showed no difference
between fatigued and control patients, whereas seven
(26.9 %) demonstrated an impaired decrease in the circa-
dian SCR. The remaining three (11.6 %) studies dis-
closed a more pronounced decrease in cortisol level.The direct awakening cortisol (DAC) level, collected at
the exact moment of waking, was used in 29 studies
(50.0 %). Unlike CAR, DAC reflects sleep quality ra-
ther than being a possible identifying factor of fatigue
[84–86], even though a poor quality sleep plays an im-
portant role in the fatigue process [87–89]. In studies
that employed DAC, inconsistent results were ob-
served: normal results were found in nineteen (65.5 %)
studies, elevated levels were shown in four (13.8 %),
and reduced levels in six (20.7 %).
The DAC, CAR and SCR methods were by far the
most commonly elected ones for examining the cor-
relation between cortisol profile and fatigue status.
However, a few other studies analyzed other aspects of
cortisol release.
The dexamethasone (Dex) suppression test (DST) was
also used in nine (15.3 %) studies. The DST identifies
autonomous hypercortisolism, as cortisol production is
normally suppressed by Dex. DSTs have also been used
to investigate hypocortisolism, based on the supposed
assumption that it promotes “oversuppression” of corti-
sol in low cortisol states, indicating that lower levels of
cortisol would disclose a more prolonged suppression
than controls [55, 90–93], although many studies do not
show correlation between DST and fatigue [47, 55, 94, 95].
In six studies, a lower Dex dose (0.5 mg) was used in an
attempt to improve the test sensitivity. Among these, four
studies (66.7 %) showed the same results for both groups,
whereas in two others (33.3 %), the test resulted in lower
and prolonged suppression of cortisol levels in fatigued
subjects. Moreover, an even lower Dex dose (0.25 mg) was
performed in two studies and resulted in reduced cortisol
in one study and normal levels in the group with exhaus-
tion. In one study, Dex dose was not specified, but levels
were not different among exhausted and control groups.
As a whole, the DST was used in nine studies, and no
significant differences were observed between fatigued
and non-fatigued groups in six of these studies
(66.7 %), whereas reduced levels were observed in
three studies (33.3 %).
Adrenocorticotropic hormone (ACTH) is a pituitary
peptide hormone that stimulates cortisol production
by the adrenocortical zona fasciculata. Elevated ACTH
occurs early in primary adrenal insufficiency, whereas
inappropriate (normal) ACTH levels in the presence of
low serum cortisol are found in secondary adrenal fail-
ure. Although, normal ACTH levels with normal corti-
sol levels does not exclude the possibility of relative
adrenocortical failure. Six (10.3 %) studies employed
the morning ACTH levels to compare fatigued and
non-fatigued patients; no significant differences for
ACTH, as well as for cortisol, were found in five stud-
ies (83.3 %), meanwhile one showed elevated ACTH
levels in burnout patients (16.7 %).
Table 2 Assessed methods and results of all selected studies (N = 58)
Procedure (*) Number of studies (% of total) Not different (%) Decreased (%) Increased (%)
DAC 29 (50.0 %) 19 (65.5 %) 6 (20.7 %) 4 (13.8 %)
CAR 27 (46.6 %) 14 (51.9 %) 9 (33.3 %) 4 (14.8 %)
SCR 26 (44.8 %) 16 (61.5 %) 7 (26.9 %) 3 (11.5 %)
MSC 22 (37.9 %) 14 (63.6 %) 4 (18.2 %) 4 (18.2 %)
NSC 22 (37.9 %) 13 (59.1 %) 3 (13.6 %) 6 (27.3 %)
AUC 13 (22.4 %) 8 (61.5 %) 3 (23.1 %) 2 (15.4 %)
DST 9 (15.5 %) 6 (66.7 %) 3 (33.3 %) -
DHEA-S 6 (10.3 %) 4 (66.7 %) 2 (33.3 %) -
ACTH 6 (10.3 %) 5 (83.3 %) - 1 (16.7 %)
MST 5 (8.6 %) 4 (80.0 %) 1 (20.0 %) -
UFC 3 (5.2 %) 1 (33.3 %) 2 (66.7 %) -
CST 3 (5.2 %) - 2 (66.7 %) 1 (33.3 %)
MAUC 3 (5.2 %) - 2 (66.7 %) 1 (33.3 %)
CAR 60 min 2 (3.4 %) 2 (100 %) - -
ACTH MST 2 (3.4 %) 2 (100 %) - -
4 PM cortisol 1 1 - -
DST + CRH cortisol 1 1 - -
DST + CRH ACTH 1 1 - -
CAR 15 min 1 1 - -
TCM 1 1 - -
DHEA-S MST 1 - 1 -
CRST cortisol 1 - 1 -
CRST ACTH 1 - 1 -
OGTT cortisol 1 - - 1
Cortisol/ACTH ratio 1 - - 1
Legends: (*): DAC direct awakening cortisol, CAR cortisol awakening response, SCR salivary cortisol rhythm, MSC morning serum (& salivary) cortisol, NSC night
salivary cortisol, AUC area under-the-curve (Estimated Cortisol Release), DST dexamethasone suppression test, DHEA-S dehydroepiandrosterone sulfate, ACTH
adrenocorticotropic hormone, MST mental stress test, UFC 24 h-urinary free cortisol, CST cosyntropin stimulation test, MAUC morning area under-the-curve
(morning estimated cortisol release), CRH corticotropin releasing hormone, TCM total urinary cortisol metabolites, CRST corticotropin releasing stimulation
test (?), OGTT oral glucose tolerance test
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dose cosyntropin (a synthetic 1-24ACTH) stimulation test
(CST), in which 1 μg of cosyntropin is used instead of
the classic 250 μg dose, based on the premise that the
CST is more accurate and sensitive for verifying the
adrenocortical cortisol reserve [96], even though most
findings indicate that both doses have similar accuracy
[97, 98]. Surprisingly, one of three (33.3 %) studies dis-
closed a paradoxically higher cortisol increase compared
to controls, while in two (66.7 %) lower levels were ob-
served. Conversely, impaired cortisol and ACTH re-
sponses was observed in the fatigued group in a single
study in which corticotropin-releasing hormone (CRH)
was used to stimulate the HPA axis.
Three (5.2 %) studies measured 24 h-urinary free cor-
tisol (UFC) in an attempt to correlate cortisol excretion
rates with intensity of fatigue. Although the 24 h-UFC
reflects the total cortisol produced per day, it wasinitially conceived to investigate cortisol excess syn-
dromes, although diminished levels could hypothetic-
ally imply subnormal adrenal function, despite of lack
of any evidence. One of these studies (33.3 %) found no
correlation between 24 h-UFC and energy status,
whereas two studies (66.7 %) showed reduced values in
fatigued patients.
Thirteen studies (22.4 %) estimated total cortisol re-
lease (AUC) by calculating the areas under the curves
for the whole day salivary cortisol collection by using
three or more daily salivary cortisol levels over four or
more days. Assessment of the total 24 h cortisol release
by this method would complement the SCR, since the
lack of the expected decrease throughout the day ob-
served in some studies can be due either to a non-
elevated morning serum cortisol (MSC) level or to a full
day elevated cortisol, although three daily levels of corti-
sol is probably too few for a minimally precise AUC;
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(15.4 %) studies, normal in eight (61.5 %), and reduced
in another three (23.1 %).
Twenty-two studies (37.9 %) compared baseline MSC
between controls and fatigued patients; traditionally
[98], this is the initial cortisol assessment to investigate
possible hypocortisolism. Basal MSC was not different
between individuals in fourteen (63.6 %) of these studies,
was significantly reduced in fatigued patients in three
(23.1 %), and was elevated in two (15.4 %).
Twenty-two articles (37.9 %) correlated late night sal-
ivary cortisol (11 PM NSC) and fatigue status. The
NSC was initially validated to assess cortisol excess, as
physiologically, one expects lower cortisol levels at the
end of the day; although, NSC has been extended to in-
vestigate hypocortisolism in these studies, despite of
lack of validation. Three studies (13.6 %) showed a
lower cortisol level in fatigued subjects compared to
controls, thirteen (59.1 %) found no differences, and six
(27.3 %) showed increased levels in fatigued subjects.
Six studies (10.3 %) investigated the correlation be-
tween dehydroepiandrosterone sulfate (DHEA-S) levels
and fatigue status. Reduced DHEA-S levels are usually
found in hypocortisolism and are a potential marker of
fatigue, although there is still not enough evidence to
corroborate this affirmation. Four studies (66.7 %) found
no correlation with DHEA-S, whereas two (33.3 %)
found lower levels in chronic exhausted patients.
The morning estimated total cortisol release (MAUC)
is obtained by calculating the area under the curves for
the period between the awakening moment and 1 hour
later, and is based on determining three or more salivary
cortisol levels during this period of the day, although
this method has also not been validated by any indexed
study. A total of four studies (6.9 %) among the selected
studies reported the MAUC. Two of these studies
(50.0 %) showed reduced MAUC levels in fatigued sub-
jects, one demonstrated increased results (25.0 %), and
one demonstrated no differences (25.0 %).
Mental stress tests (MST) have been performed in
some studies in order to identify possible differences in
cortisol and ACTH release between fatigued and non-
fatigued individuals. The most employed test was the Trier
Social Stress Test (TSST), which has been already vali-
dated as a stress trigger test [99–102], and requires
complete HPA axis integrity for a proper response. Other
types of MSTs have also been proposed and validated
[103, 104]. MSTs were performed in five different studies
in order to correlate cortisol and ACTH responses and
burnout status. No difference was seen in four studies
(80.0 %), whereas in one (20.0 %), cortisol and ACTH
responses were impaired in exhausted individuals.
Some other tests were performed in a smaller number
of the selected studies, as follows: two studies performeda 60 min CAR (both showed normal results among fa-
tigued and non-fatigued subjects); one study performed a
15 min CAR (and showed normal results); two studies
performed the ACTH MST (both used the TSST and
found normal results); one study performed the DHEA-S
MST (which also used the TSST and demonstrated normal
results); one study performed the cortisol post Oral Glu-
cose Tolerance Test (OGTT) (and found no differences
among fatigued and non-fatigued subjects); one study cal-
culated cortisol/ACTH ratio (and found an increased ratio
among exhausted subjects); one study evaluated the 4 PM
cortisol level (and found no significant differences between
exhausted subjects and controls); one study used 1.5 mg-
Dex followed by 0.1 mg-CRH to stimulate cortisol and
ACTH (and showed normal responses); one study stimu-
lated ACTH and cortisol with 0.1 mg of CRH (and found
reduced levels of both hormones in fatigued subjects com-
pared to controls); and finally, one study evaluated the
multiple urinary cortisol metabolites and calculated the
Total Cortisol Metabolites (TCM) (and found no differ-
ences between fatigued subjects and controls).
Finally, we were not able to find studies in which the
gold standard test for assessing the integrity and func-
tionality of the HPA axis—the insulin tolerance test
(ITT)—were performed. The same was true for the lipo-
polysaccharides (LPS) stimulation test. Both tests stimu-
late hypothalamic CRH secretion, leading to a complete
evaluation of the HPA axis.
Fatigue in burnout syndrome
Burnout syndrome or clinical burnout, or simply “burn-
out”, refers to a decrease in the cognitive functions, emo-
tional exhaustion, and physical fatigue that is triggered by
stressful situations associated with excessive working
[105]. However, there is no pathognomonic marker for
burnout [105]. For practical purposes, we considered non-
CFS burnout patients as “healthy”, as burnout is yet to be
considered a disease and its characterization is still hetero-
geneous. A summary of the performed methods and their
respective results in non-CFS burnout/healthy patients
[21–53] are shown in Table 3. Assessment of the HPA axis
integrity in burnout patients (at the pituitary and hypo-
thalamic levels) has not been determined.
Fatigue in chronic fatigue syndrome
CFS is a diagnosis used for patients who present severe
fatigue for more than six months, not explained by any
hormonal, metabolic, inflammatory, or other disorders.
Correlations between CFS and the HPA axis have been
studied [54–66] and the results are shown in Table 4.
Fatigue in other disorders
Complaints regarding fatigue not entirely explained by
the underlying pathophysiology of the disease have been
Table 3 Studies in Burnout syndrome and healthy subjects (N = 33): Methods of assessment and respective results
Procedure Number of studies (% of total) Not different (%) Decreased (%) Increased (%)
DAC 17 (51.5 %) 10 (58.8 %) 4 (23.5 %) 3 (17.7 %)
CAR 16 (48.5 %) 9 (56.2 %) 6 (37.5 %) 1 (6.3 %)
MSC 12 (36.4 %) 8 (66.7 %) 1 (8.3 %) 3 (25.0 %)
SCR 12 (36.4 %) 7 (58.3 %) 3 (25.0 %) 2 (16.7 %)
NSC 10 (30.3 %) 7 (70.0 %) 2 (20.0 %) 1 (10.0 %)
DST 7 (21.2 %) 5 (71.4 %) 2 (28.6 %) -
MST 5 (15.2 %) 4 (80.0 %) 1 (20.0 %) -
DHEA-S 5 (15.2 %) 3 (60.0 %) 2 (40.0 %) -
ACTH 4 (10.1 %) 3 (75.0 %) - 1 (25.0 %)
AUC 3 (9.1 %) 2 (66.7 %) 1 (33.3 %) -
ACTH MST 2 (6.1 %) 2 (100 %) - -
CST 2 (6.1 %) - 1 (50 %) 1 (50 %)
4 PM cortisol 1 1 - -
DST + CRH cortisol 1 1 - -
DST + CRH ACTH 1 1 - -
CAR 15 min 1 1 - -
CAR 60 min 1 1 - -
DHEA-S MST 1 - 1 -
UFC 1 - 1 -
OGTT cortisol 1 - - 1
Cortisol/ACTH ratio 1 - - 1
Legends: (*): DAC direct awakening cortisol, CAR cortisol awakening response, MSC morning serum (& salivary) cortisol, SCR salivary cortisol rhythm, NSC night
salivary cortisol, DST dexamethasone suppression test, MST mental stress test, DHEA-S dehydroepiandrosterone sulfate, ACTH adrenocorticotropic hormone,
AUC area under-the-curve (estimated cortisol release), CST cosyntropin stimulation test, CRH corticotropin releasing hormone, UFC 24 h-urinary free cortisol,
OGTT oral glucose tolerance test
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such as chronic low back pain [106, 107], breast cancer
survivors [108–110], and HIV [111, 112]. Therefore,
the role of the HPA axis in the etiology of fatigue in
these subjects has been analyzed [67–77] and the find-
ings are presented in Table 5.Table 4 Studies in Chronic Fatigue Syndrome (N = 13): Methods of
Procedure Number of studies (% of total) Not
MSC 8 (61.5 %) 5 (6
SCR 6 (46.2 %) 5 (8
AUC 6 (46.2 %) 3 (5
NSC 5 (38.5 %) 4 (8
DAC 3 (23.1 %) 3 (1
CAR 3 (23.1 %) 2 (6
ACTH 2 (15.4 %) 2 (1
DST 2 (15.4 %) 1 (5
UFC 2 (15.4 %) 1 (5
CST 1 (7.7 %) -
Legends: (*): MSC morning serum (& salivary) cortisol, SCR salivary cortisol rhythm, A
DAC direct awakening cortisol, CAR cortisol awakening response, ACTH adrenocortic
cortisol, CST cosyntropin stimulation testQuestionnaires for fatigue assessment
Among all studies included in this review, nineteen
different types of questionnaires and scores were re-
ported. The most commonly used were: the Maslach
Burnout Inventory (MBI, n = 15), SF-36 (n = 9), the
Chalder Fatigue Scale (CFS, n = 8), the Generalassessment and respective results
different (%) Decreased (%) Increased (%)
2.5 %) 2 (25.0 %) 1 (12.5 %)
3.3 %) 1 (16.7 %) -
0.0 %) 2 (33.3 %) 1 (16.7 %)
0.0 %) 1 (20.0 %)
00.0 %) - -
6.7 %) 1 (33.3 %) -
00.0 %) - -
0.0 %) 1 (50.0 %) -
0.0 %) 1 (50.0 %) -
1 (100.0 %) -
UC area under-the-curve (estimated cortisol release), NSC night salivary cortisol,
otropic hormone, DST dexamethasone suppression test, UFC 24 h-urinary free
Table 5 Studies in Other Disorders (N = 12): Methods of and respective results
Procedure Number of studies (% of total studies) Not different (%) Decreased (%) Increased (%)
DAC 9 (75.0 %) 6 (66.7 %) 2 (22.2 %) 1 (11.1 %)
SCR 8 (66.7 %) 4 (50.0 %) 3 (37.5 %) 1 (12.5 %)
CAR 8 (66.7 %) 3 (37.5 %) 2 (25.0 %) 3 (37.5 %)
NSC 7 (58.3 %) 2 (28.6 %) - 5 (71.4 %)
AUC 4 (33.3 %) 3 (75.0 %) - 1 (25.0 %)
MSC 2 (16.7 %) 1 (50.0 %) 1 (50.0 %) -
DHEA-S 1 (8.3 %) 1 (100.0 %) - -
Legends: (*): DAC direct awakening cortisol, SCR salivary cortisol rhythm, CAR cortisol awakening response, NSC night salivary cortisol, AUC area under-the-curve
(estimated cortisol release), MSC morning serum (& salivary) cortisol, DHEA-S Dehydroepiandrosterone sulfate
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tory (MFI, n = 6) and the Shirom Melamed Burnout
Questionnaire (n = 6). In ten studies, more than one
type of survey was performed. In four studies, the
methods to assess fatigue were not specified or
assessed. A summary of the assessed questionnaires is
shown in Table 6.Table 6 Assessed questionnaires employed in the selected studies (
Questionnaire Gene
Maslach Burnout Inventory 15 (2
SF-36-Short Form Health Survey 36 9 (15
CFQ-Chalder Fatigue Questionnaire 8 (13
SMBQ - Shirom-Melamed Burnout Questionnaire 6 (10
MFI-Multidimensional Fatigue Inventory 6 (10
DCSRD: Diagnosis criteria of stress-related exhaustion disorder 3 (5.
Maastricht Vital Exhaustion Questionnaire 2 (3.
FAQ-Fatigue Assessment Questionnaire 2 (3.
NC-WHO-Neurasthenia Criteria 2 (3.
POMS-Profile of Mood States 2 (3.
SOFI-Swedish Occupational Fatigue Inventory 1
ADAS-Abbreviated Dyadic Adjustment Scale 1
SEQ-Exclusion with Stress-Energy Questionnaire 1
MP-Memory performance 1
Stress Tasks 1
NRWS - Need for Recovery from Work Scale 1
FSE-Fatigue Severity Scale 1
HRFS-HIV-related Fatigue Scale 1
BFI: Brief Fatigue Inventory 1
More than one questionnaire 10 (1
Stress tests 5 (8.
Not specified 4 (6.
Legends: Maslach maslach burnout inventory, SF-36 short form health survey 36, CFQ c
MFI multidimensional fatigue inventory, DCSRD diagnosis criteria of stress-related
FAQ fatigue assessment questionnaire, NC-WHO neurasthenia criteria, POMS profile of
dyadic adjustment scale, SEQ stress-energy questionnaire, MP memory performance, S
HRFS HIV-related fatigue scale, BFI brief fatigue inventoryDiscussion
Theories on adrenal impairment as the genesis for
fatigue are tempting, as they allow for a treatable condi-
tion. Despite the widespread use of the term “adrenal
fatigue” by the general media and certain health practi-
tioner groups, in this systematic review, only ten cita-
tions [113–122] were found with this exact expression,N = 58)
ral Healthy/Burnout CFS Other diseases
5.7 %) 15 - -
.5 %) 4 3 2
.8 %) 1 4 3
.3 %) 6 - -
.3 %) - 2 4
2 %) 3 - -
4 %) 2 - -
4 %) - - 2
4 %) 1 1 -










7.2 %) 6 3 1
6 %) 5 - -
9 %) - 4
halder fatigue questionnaire, SMBQ shirom-melamed burnout questionnaire,
exhaustion disorder, Maastricht Maastricht vital exhaustion questionnaire,
mood states, SOFI Swedish occupational fatigue inventory, ADAS abbreviated
tress Tasks; NRWS need for recovery from work scale, FSE fatigue severity scale,
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any test regarding the HPA axis and “adrenal fatigue”.
Studies that tried to correlate the HPA axis and fatigue
states used the term “burnout” instead of “adrenal fatigue”
to denote adrenal depletion. Therefore, a distinction
between the “general information” and the actual scien-
tific literature regarding this condition is evident. First,
this suggests that the terminology of a hypothetical
adrenal depletion should be normalized, with a suitable
name given for the purported condition, as “adrenal
fatigue” has been already been stigmatized and lacks
proper scientific support. Second, methodology employed
to evaluate the proposed correlation between fatigue and
adrenal function should be standardized among physicians
and medical associations that claim for the existence of
adrenal impairment in patients with fatigue before evident
clinical hypocortisolism manifests, in order to strength
eventual evidence, in case one finds actual and proper
causal correlation.
No confirmed methods of clinical screening for AF are
available. Indeed, the popular questionnaire developed
by Dr. Wilson and published in the first book exclusively
dedicated to the description of this supposedly disease
[6] has not been cited in any indexed databases. Another
theory, the “Thompson cortisol hypothesis” [123], sug-
gests that cortisol is responsible for yawning and fatigue;
however, again, no studies that tested this theory have
been published in indexed journals. Validated surveys
have been used in studies that investigate fatigue states,
but they were not correlated with proper cortisol assess-
ment methods. The TSST is the only survey to have
enough credibility to be officially tested and standardized
as a trigger of stress [99–102].
Functional tests are the only methods to assess adrenal
cortisol production endorsed by endocrinology societies
[97]. Although, the ITT is considered the gold standard
test to evaluate the entire HPA axis, neither the ITT (or
the similar LPS stimulation test) was performed in any
studies investigating the correlation between fatigue
states and adrenocortical function. Moreover, we gener-
ally found conflicting data using most of the functional
tests when trying to differentiate exhausted, fatigued,
and burnout individuals from healthy patients. For ex-
ample, using the low-dose CST, we found an unexpected
increase in cortisol levels in fatigued subjects in the
selected studies. This may have been perhaps the result
of a relative secondary adrenal insufficiency, which leads
to an amplified adrenal cortisol response due to an up-
regulation of ACTH receptors, but this sounds unjustifi-
able since the lack of continuous stimulation of the
adrenal cortices would cause atrophy, rendering them
non-responsive to a low- (and even high) dose of cosyn-
tropin stimulation in the long run. Regardless of the the-
oretical explanation, CST has shown to be not a goodmarker of fatigue. Similarly, ACTH levels were also
poorly studied and did not show significant correlations
in most fatigued subjects. In addition, despite its lack of
standardization, the DST was performed in nine studies,
but conflicting results invalidated attempts to establish
this as a new marker for fatigue states. Moreover, the
24 h-UFC has been shown to be so far inaccurate for
investigation of adrenal impairment. Findings were also
contradictory in the six studies that calculated cortisol
AUC as well as in the four studies that performed
MAUC. Therefore, the above methods cannot be used to
differentiate fatigued from non-fatigued individuals.
In this review, we also examined whether cortisol
markers can be used to assess cortisol impairment. The
results of our review indicate that the three major tests
(CAR, DAC and SCR) used to identify the underlying
causes of the fatigue/exhaustion state failed to do so, since
they were unable to demonstrate significant differences or
proper causality. CAR and DAC frequently showed incon-
sistent results in studies that used heterogeneous groups
of subjects. CAR and DAC are not necessarily indicatives
of the etiology and pathogenesis of the fatigue status, since
both can be consequences of other disorders, such as
sleep disturbances. Indeed, a recent study [124] was the
first to use CAR as a marker of improvement of burnout
syndrome, which reinforces the use of this method for
monitoring the consequences of fatigue states, but not for
its etiology [77–81].
With regards to the SCR, the results may be misleading
if they are not analyzed together with the total 24 h corti-
sol release. This is because a non-physiological blunted
rhythm can be due either to an impairment of the lower-
ing cortisol trend throughout the day or due to a lower
morning cortisol level. Despite this, studies that evaluated
total 24 h cortisol by measuring serial salivary cortisol
levels also showed conflicting findings. Our systematic
review corroborates another systematic review [83] that
shows inconsistency regarding measuring methods among
across different randomized controlled trials. Similarly,
baseline MSC and NSC were poor markers of fatigue sta-
tus as it failed to reveal any differences in burnout/exhaus-
tion/fatigue patients compared to healthy subjects.
Adrenal size could be considered another marker of
adrenal activity, as hypertrophic/hyperplastic adrenal
glands could be the result of an ACTH over-stimulation
by the pituitary, as seen in subjects exposed to chronic
stress [125, 126], whereas a diminished or atrophic gland
may reflect adrenal insufficiency at any level of the HPA
axis [98]. However, not a single study could be identified
in which the adrenal size has been checked in fatigued
or exhausted patients. Similarly, although DHEA-S
could also be a potential marker for adrenal atrophy or
dysfunction, is still uncertain whether it plays any
pathophysiological role in fatigue. Finally, none of the
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tigue, nor could they be correlated with the HPA axis
dysfunction as an etiology of fatigue.
It is also important to note that once adrenal impair-
ment is confirmed using any of these tests, the etiology
should also be elucidated. As the HPA axis can be
affected by several chronic and/or metabolic disorders,
other primary conditions must be excluded before
intrinsic disorders of the HPA axis are deemed respon-
sible. Typical differential diagnosis of “adrenal fatigue”
and related states are: (1) sleep obstructive apnea syn-
drome; (2) adrenal insufficiency; (3) mental illnesses; (4)
excessive working (overwork); (5) night-shift workers; (6)
other hormonal deficiencies; (7) liver and kidney dys-
functions; (8) heart conditions; (9) chronic pulmonary
obstructive disease; (10) autoimmune diseases.
Although conflicting data were reported, patients with
CFS tend to have a normal cortisol profile, and the ab-
normalities found can be typically be explained by a
poor quality sleeping patterns. Therefore, health pro-
viders should not be concerned about adrenal function
in CFS subjects once they had been already excluded to
other conditions prior to the diagnosis of CFS. Similarly,
studies investigating patients with the burnout syndrome
were greatly inconsistent So far, HPA axis tests should
not be used as markers for burnout syndrome by health
practitioners. Similar conclusions can be drawn for the
use of HPA axis tests as markers for fibromyalgia and
other chronic diseases, which tend to demonstrate in-
consistent findings, whereas studies that were performed
in breast cancer subjects tended to show depletion of
cortisol levels; however, studies in breast cancer were
performed while administering chemotherapy, which
can introduce a confounding bias.
Therefore, based on our current knowledge, cortisol
tests should not yet be used in clinical practice for
examining any condition, except if adrenal impairment
is suspected. Moreover, glucocorticoid therapy should be
avoided in patients, as it can increase the risk of cardio-
vascular disease or osteoporosis, even in low doses.
Limitations
Some limitations of this review include: (1) our inability
to perform a meta-analysis due to heterogeneity of the
study design; (2) the descriptive nature of most studies,
and the reporting of a condition that has not been scientif-
ically proven without adding new data nor providing solid
arguments; (3) the fact that most studies were published
in low impact journals; (4) the inadequate and poor qual-
ity assessment of fatigue; (5) the use of an unsubstantiated
methodology in terms of cortisol assessment; (6) the lack
of concern regarding validated adrenal assessment (as en-
dorsed by endocrinologists); (7) false premises leading to
an incorrect sequence of thinking and research direction;and, (8) inappropriate/invalid conclusions regarding caus-
ality and association between different information, in
particular, whether any abnormalities would be a
marker or a potential target for treatment.
Final discussions
Our results corroborate an Endocrine Society warning
statement regarding adrenal fatigue (1), as saying that
“adrenal fatigue is not a real medical condition”. While a
recent systematic review on burnout was published
(109) that implicated some HPA dysfunctions as markers
or triggers of burnout, there were important bias selection
regarding the articles chosen. Therefore, we recommend
that for further prospective studies aiming to correlate fa-
tigue, exhaustion, or burnout status with impairment of the
HPA axis, an ITT or a 250 μg CST should be performed to
evaluate the adrenocortical ability to release cortisol,
measurements of ACTH, DHEA-S, and corticosterone (an
intermediate steroid product that is impaired earlier than
cortisol [127]), the adoption of the most validated question-
naires, particularly Maslach Burnout Inventory, the Chalder
Fatigue Scale, SF-36 or the General Fatigue Scale of the
Multidimensional Fatigue Inventor, and considering differ-
ent study populations, including: (a) healthy subjects; (b)
burnout healthy subjects; (c) subjects with overtraining
syndrome; (d) subjects post-chemotherapy; (e) subjects
with CFS; and (f) subjects with fibromyalgia.
In addition, we do not recommend the use of the
many methods reported in the articles evaluated in this
systematic review, as they are not accurate to determine
whether a patient has or has not adrenal failure.
The answer to whether “adrenal fatigue” or depletion
exists or not may not be simple, but different answers
can be offered according to the presence of an under-
lying disease. However, so far, there is no substantiation
to show its existence.
Conclusion
To our knowledge, this is the first systematic review
made by endocrinologists to examine a possible correl-
ation between the HPA axis and a purported “adrenal
fatigue” and other conditions associated with fatigue,
exhaustion or burnout. So far, there is no proof or dem-
onstration of the existence of “AF”. While a significant
number of the reported studies showed differences
between the healthy and fatigued groups, important
methodological issues and confounding factors were
apparent. Two concluding remarks emerge from this
systematic review: (1) the results of previous studies
were contradictory using all the methods for assessing
fatigue and the HPA axis, and (2) the most appropriate
methods to assess the HPA axis were not used to evaluate
fatigue. Therefore, “AF” requires further investigation
by those who claim for its existence.
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